Cell Therapy
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Global cell therapy market intelligence for pharma BD, investors & analysts. Stay ahead of CAR-T, stem cell, and regenerative medicine trends.
Showing 1–12 of 17 articles
Quick answer
NovaPharmaNews Cell Therapy hub for FDA covers 17 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Legend Biotech surges on early in vivo CAR-T data for lymphoma
Allogene CEO David Chang Steps Down: Implications for the Biotech Sector
Cencora-Kite Agreement: A New Era for CAR T-cell Therapy Commercialization
Legend Biotech's In Vivo CAR-T Data Sparks Stock Surge: A Catalyst Tracking Analysis
Legend Biotech Presents Promising CARVYKTI and LB2102 Data at ASCO
BioMed Israel: Daily Highlights and Key Takeaways
ASGCT: Key Manufacturing Innovations Day 1
ASGCT 2024: Gene Therapy Advancements Day 1 Roundup
ASGCT 2024: Day 1 Key Takeaways in Gene Therapy Advancements
ASGCT 2026: Manufacturing Innovations Day 1 Roundup
ASGCT 2024: Gene Therapy Advancements Take Center Stage
Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.